StockNews.com began coverage on shares of Zimmer Biomet (NYSE:ZBH – Get Rating) in a report published on Thursday morning. The firm issued a buy rating on the medical equipment provider’s stock.
Several other research firms have also recently weighed in on ZBH. JMP Securities reissued a market outperform rating and issued a $145.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, February 7th. Robert W. Baird raised their target price on Zimmer Biomet from $133.00 to $145.00 in a research report on Monday, February 6th. Royal Bank of Canada raised Zimmer Biomet from a sector perform rating to an outperform rating and raised their target price for the stock from $125.00 to $141.00 in a research report on Monday, January 9th. Loop Capital raised their target price on Zimmer Biomet from $125.00 to $140.00 in a research report on Monday, February 6th. Finally, Morgan Stanley raised their target price on Zimmer Biomet from $135.00 to $140.00 and gave the stock an equal weight rating in a research report on Monday, February 6th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $133.56.
Zimmer Biomet Stock Down 0.9 %
ZBH opened at $124.31 on Thursday. Zimmer Biomet has a 1-year low of $100.39 and a 1-year high of $135.05. The company has a current ratio of 1.88, a quick ratio of 0.97 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $26.11 billion, a price-to-earnings ratio of 113.01, a P/E/G ratio of 2.87 and a beta of 1.00. The business has a 50 day moving average of $125.21 and a 200-day moving average of $118.70.
Zimmer Biomet Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Wednesday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. Zimmer Biomet’s payout ratio is presently 87.27%.
Institutional Trading of Zimmer Biomet
A number of hedge funds and other institutional investors have recently made changes to their positions in ZBH. Creative Capital Management Investments LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $25,000. New England Capital Financial Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $27,000. Clear Street Markets LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $27,000. Guardian Wealth Advisors LLC acquired a new stake in shares of Zimmer Biomet in the third quarter valued at $28,000. Finally, US Asset Management LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $33,000. 87.21% of the stock is currently owned by institutional investors and hedge funds.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.
- Get a free copy of the StockNews.com research report on Zimmer Biomet (ZBH)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.